It's astounding the lack of front page news with these numbers from BoM ... should be EVERYWHERE ... the "retail" strategy and tactics are confusing, at best. Some very "elementary" marketing and PR efforts could be huge. Why would retailers buy, if RVX is not selling? I liked that approach for a while, but with a longer term position again, I would really appreciate some marketing to make me "feel better" about holding for a few years again, potentially, which I'm gonna do regardless ... while hoping for a BP white knight to pop onto the scene.

They just don't seem to be "retail" focused, at all. And i just don't get it ... maybe they just feel they need to stay under the radar working on the science, while they sort out the drug, opportunity, partnering (the bigger fish)?!

I wonder how a BP would be handling the PR if apabetalone was within a BP's portfolio? ... probably beneath the radar also to an extent?

Ugh, oh well, still very excited about the future.